Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice

Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer

Núbia Muñóz, F. Xavier Bosch, Sílvia de Sanjosé et al. · New England Journal of Medicine · 2003 · 6.3K citations · Full text

Medicine, Oncology, Pathology +17

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Diane M. Harper, Eduardo L. Franco, Cosette M. Wheeler et al. · The Lancet · 2006 · 1.6K citations · Full text

Veterinary Medicine, Immunology, Oncology +16

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Reinhard Kirnbauer, Frank P. Booy, N. Cheng et al. · Proceedings of the National Academy of Sciences · 1992 · 1.1K citations

Life Sciences, Immunology, Molecular Biology +17

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

JoAnn Suzich, S. Ghim, Frances J. Palmer‐Hill et al. · Proceedings of the National Academy of Sciences · 1995 · 671 citations

Life Sciences, Immunology, Infectious Diseases +17

Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles

Reinhard Kirnbauer, Jeffrey W. Taub, Heather L. Greenstone et al. · Journal of Virology · 1993 · 610 citations · Full text

Life Sciences, Microbiology, Molecular Biology +17